P01.24 Ramucirumab + Docetaxel (DOC) vs PBO + DOC for Stage IV NSCLC after Disease Progression (REVEL): Indian Sub-Group Analysis
2021
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI